Muscoside A is a combination of Thiocolchicoside and Aceclofenac. Thiocolchicoside is a sulphurated semi-synthetic derivative of colchicoside. It is a myorelaxant, which acts as GABA-A receptor antagonist. It also has powerful convulsant activity and not to be used in seizures patients. Aceclofenac is a phenylacetic acid derivative which produces its action on inflammatory mediators. It is a glycolic acid ester of diclofenac.
- Muscoloskeleton and neuromuscular spasm
- Acute back pain in lower portion
- Post operative pain
- Pain in neck and shoulder
It is a muscle relaxant which possesses anti-inflammatory and analgesic property. It produces its action by displacing [3H] GABA and [3H] strychnine binding by interacting with the respective receptor.
It is a NSAID which produces its action by blocking COX-1 which is involved in inflammatory processes. This inflammatory mediators produces response to any injury and cause pain and swelling. It is a glycolic acid ester of diclofenac.
After oral administration it is well absorbed in the body.
About 99.7% of the drug is bound to plasma protein. It produces its action by concentrating in synovial fluid. The drug is metabolized in liver as 4-hydroxyaceclofenac.
It is excreted as conjugated metabolites through urine.
After oral administration it is initially not detected in the plasma. One metabolite which is active is SL18.0740. The maximum plasma concentration occurs in 1hr.
After oral administration it is well absorbed and it is bound to plasma. The volume of distribution is more for thiocolchicoside to produce pharmacological action. The metabolism of the drug is in intestine. In intestine the drug is glucuroconjugated to produce the pharmacological action.
Nearly about 75% of the drug is excreted in feces and about 20% of the drug is excreted in urine. The whole drug after administration is absorbed and not excreted as unchanged form.
- Hypersensitivity to any of the component present in the drug
- Patients with asthma, bronchospasm or acute rhinitis
- Cautiously used in epileptic patients and patients with convulsions
- Lower dose should be used in patients with diarrhea
- Patients with blood disorder
- History of peptic ulcer
- Stomach disorder
- Hepatic porphyria
- In pregnant patients